Chinese CRISPR play CureGenetics raises $17M series A

CureGenetics Co. Ltd. (Suzhou, China) raised $17 million in a series A round led by new investor Qiming Venture Partners. CTS Capital and Ascendin Investment also participated.

CureGenetics uses its CRISPR-based gene editing technology to knock out genes related to immune rejection to develop universal, allogeneic CAR T cells that are suitable for combination with different CAR and TCR molecules...